Multiobjective Genetic Algorithm applied to dengue control

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Galectin-1 exerts inhibitory effects during DENV-1 infection

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Vaccination of sheep and cattle against haemonchosis

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Immunomodulatory activity and control of Salmonella Enteritidis colonization in the intestinal tract of chickens by Lactobacillus based probiotic

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Biomassa da bactéria Rubrivivax gelatinosus proveniente do tratamento de efluente de piscicultura melhora a saúde dos peixes

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Avaliação sorológica de vacinas comerciais polivalentes contra a enterotoxemia em caprinos

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Dendrimers as potential platform in nanotechnology-based drug delivery systems

The dendrimers of poly (amidoamine) (PAMAM) are nanoparticles which have proven succeed in transporting drugs due to high solubility, low toxicity and ability to control drugs release. Studies have explored the biological potential of dendrimers such as to transport genes, development of vaccines, antiviral, antibacterial and anticancer therapies. This review of literature on the PAMAM dendrimers discusses the architecture and general construction of dendrimers and intrinsic properties of the PAMAM. This study also describes how the PAMAM interact with many drugs and the potential of these macromolecules as well as drug nanocarriers in transdermal routes of administration, ocular, respiratory, oral and intravenous administration. Dendrimers promises good future prospects for the biomedicine.

Dificuldades encontradas no programa de revacinação dos pacientes submetidos ao transplante de células tronco hematopoiéticas

Pós-graduação em Pesquisa e Desenvolvimento (Biotecnologia Médica) - FMB

Imunohistoquímica em órgãos de tilápias-do-Nilo imunizadas com antígeno insolúvel de Streptococcus agalactiae

Pós-graduação em Medicina Veterinária - FCAV

Avaliação da participação e confiabilidade da população em relação à campanha de vacinação anual contra a raiva de cães e gatos no município de Botucatu, São Paulo, Brasil

The annual vaccination campaign against rabies is the most effective prevention procedure for this disease in dogs and cats and hence for human protection also. However, in 2010 and 2011, this activity was interrupted in Brazil due to the occurrence of adverse events associated with vaccination. Even though cases of canine rabies have been decreasing in the last two decades, vigilance must be strengthened in order to maintain pet owners trust in the vaccines provided in public services. This study aimed to determine pet owners participation in the annual vaccination campaign carried out in Botucatu. During March and April 2012, the period before the 42nd campaign, 312 pet owners, dogs and cats, were interviewed. The homes were randomly drawn in blocks from different sectors of the city; all houses on the same block over the 120 km² of urban area participated in the sampling process. Statistical analysis was performed descriptively. The results showed that the owners main motivation to vaccinate their pets during the campaigns is rabies prevention (36%), followed by the proximity of the vaccination station to the house (20.7%), zero cost (10.9%), and the combination of all three factors (16.1%). When asked if they would take their animals back to be vaccinated in another campaign, 60.1% answered yes, 13.5% would go to a private clinic, 2.2% would not take because they do not trust the vaccine and 1.6% had not decided yet. We conclude that the respondents have realized how dangerous Rabies is, because even after the break period, they still utilized the vaccination campaign demonstrating confidence in its effectiveness, while knowing the campaign goals facilitates understanding and participation.

Avaliação do conhecimento dos enfermeiros da rede de atenção à saúde do município de Botucatu sobre DPOC

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Conhecimento sobre HPV (Papilomavírus Humano) e a percepção das adolescentes sobre sua imunização

Pós-graduação em Enfermagem (mestrado profissional) - FMB

Plasmodium vivax Duffy binding protein: baseline antibody responses and parasite polymorphisms in a well-consolidated settlement of the Amazon Region

Objective To investigate risk factors associated with the acquisition of antibodies against Plasmodium vivax Duffy binding protein (PvDBP) a leading malaria vaccine candidate in a well-consolidated agricultural settlement of the Brazilian Amazon Region and to determine the sequence diversity of the PvDBP ligand domain (DBPII) within the local malaria parasite population. Methods Demographic, epidemiological and clinical data were collected from 541 volunteers using a structured questionnaire. Malaria parasites were detected by conventional microscopy and PCR, and blood collection was used for antibody assays and molecular characterisation of DBPII. Results The frequency of malaria infection was 7% (6% for P. vivax and 1% for P. falciparum), with malaria cases clustered near mosquito breeding sites. Nearly 50% of settlers had anti-PvDBP IgG antibodies, as detected by enzyme-linked immunosorbent assay (ELISA) with subjects age being the only strong predictor of seropositivity to PvDBP. Unexpectedly, low levels of DBPII diversity were found within the local malaria parasites, suggesting the existence of low gene flow between P. vivax populations, probably due to the relative isolation of the studied settlement. Conclusion The recognition of PvDBP by a significant proportion of the community, associated with low levels of DBPII diversity among local P. vivax, reinforces the variety of malaria transmission patterns in communities from frontier settlements. Such studies should provide baseline information for antimalarial vaccines now in development.

HIV-1 induces NALP3-inflammasome expression and interleukin-1 beta secretion in dendritic cells from healthy individuals but not from HIV-positive patients

Objective: NALP3-inflammasome is an innate mechanism, alternative to type-1 interferon, which is able to recognize nucleic acids and viruses in the cytoplasm and to induce pro-inflammatory response. Here, we hypothesized the involvement of inflammasome in the early defense against HIV-1 and in the full maturation of dendritic cells: for this, we evaluated the response of dendritic cells pulsed with HIV-1 in terms of inflammasome activation in healthy donors. Moreover, inflammasome response to HIV was evaluated in HIV-infected individuals. Design and methods: Monocyte-derived dendritic cells isolated from 20 healthy individuals (HC-DC) and 20 HIV-1-infected patients (HIV-DC) were pulsed with alditrithiol-2-inactivated HIV-1. We then analyzed inflammasome genes expression and interleukin-1 beta (IL-1 beta) secretion. Results: In HC-DC, HIV-1 induced higher NLRP3/NALP3 mRNA expression compared with other inflammasome genes such as NALP1/NLRP1 or IPAF/NLRC4 (P < 0.001). This augmented expression was accompanied by CASP1-increased and IL1B-increased mRNA levels and by a significant increment of IL-1b secretion (P < 0.05). Otherwise, HIV-1 failed to activate inflammasome and cytokine production in HIV-DC. HIV-DC showed an increased NLRP3/NALP3 basal expression, suggesting a chronic inflammatory profile of patients' immune cells. Conclusion: HIV-1 was able to induce a NALP3-inflammasome response in healthy individuals, indicating that this inflammasome could play a role in the first steps of HIV-1 infection; the consequent inflammatory process may be important for directing host immune response against the virus and/or disease progression. HIV-DC seemed to be chronically activated, but unresponsive against pathogens. Our findings could be of interest considering the ongoing research about dendritic cell manipulation and therapeutic strategies for AIDS involving dendritic cell-based immune-vaccines. (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins

Broad and Cross-Clade CD4(+) T-Cell Responses Elicited by a DNA Vaccine Encoding Highly Conserved and Promiscuous HIV-1 M-Group Consensus Peptides

T-cell based vaccine approaches have emerged to counteract HIV-1/AIDS. Broad, polyfunctional and cytotoxic CD4(+) T-cell responses have been associated with control of HIV-1 replication, which supports the inclusion of CD4(+) T-cell epitopes in vaccines. A successful HIV-1 vaccine should also be designed to overcome viral genetic diversity and be able to confer immunity in a high proportion of immunized individuals from a diverse HLA-bearing population. In this study, we rationally designed a multiepitopic DNA vaccine in order to elicit broad and cross-clade CD4(+) T-cell responses against highly conserved and promiscuous peptides from the HIV-1 M-group consensus sequence. We identified 27 conserved, multiple HLA-DR-binding peptides in the HIV-1 M-group consensus sequences of Gag, Pol, Nef, Vif, Vpr, Rev and Vpu using the TEPITOPE algorithm. The peptides bound in vitro to an average of 12 out of the 17 tested HLA-DR molecules and also to several molecules such as HLA-DP, -DQ and murine IA(b) and IA(d). Sixteen out of the 27 peptides were recognized by PBMC from patients infected with different HIV-1 variants and 72% of such patients recognized at least 1 peptide. Immunization with a DNA vaccine (HIVBr27) encoding the identified peptides elicited IFN-gamma secretion against 11 out of the 27 peptides in BALB/c mice; CD4(+) and CD8(+) T-cell proliferation was observed against 8 and 6 peptides, respectively. HIVBr27 immunization elicited cross-clade T-cell responses against several HIV-1 peptide variants. Polyfunctional CD4(+) and CD8(+) T cells, able to simultaneously proliferate and produce IFN-gamma and TNF-alpha, were also observed. This vaccine concept may cope with HIV-1 genetic diversity as well as provide increased population coverage, which are desirable features for an efficacious strategy against HIV-1/AIDS.